- Home
- DXR vs CING Comparison
DXR vs CING Comparison
Compare DXR & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | CING |
|---|---|---|
| Founded | 1970 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 64.5M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DXR | CING |
|---|---|---|
| Price | $10.00 | $5.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 1.6K | ★ 133.1K |
| Earning Date | 02-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | $74.79 | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.56 | $3.16 |
| 52 Week High | $14.76 | $11.89 |
Technical Indicators
Market Signals| Indicator | DXR | CING |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 64.61 |
| Support Level | $9.64 | $4.76 |
| Resistance Level | $11.16 | $5.54 |
| Average True Range (ATR) | 0.20 | 0.27 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 4.78 | 94.93 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.